Bicara Therapeutics (BCAX) Insider Trading & Ownership $11.75 -0.18 (-1.51%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$11.74 -0.01 (-0.04%) As of 07/25/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Bicara Therapeutics (NASDAQ:BCAX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage15.50%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$34.25MNumber OfInsiders Selling(Last 12 Months)0 Get BCAX Insider Trade Alerts Want to know when executives and insiders are buying or selling Bicara Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address BCAX Insider Buying and Selling by Quarter Bicara Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/17/2024James E FlynnMajor ShareholderBuy70,000$18.00$1,260,000.00 9/16/2024Ra Capital Management, L.P.DirectorBuy1,833,000$18.00$32,994,000.00 (Data available from 1/1/2013 forward) BCAX Insider Trading Activity - Frequently Asked Questions Who is on Bicara Therapeutics' Insider Roster? The list of insiders at Bicara Therapeutics includes James E Flynn, and Ra Capital Management, L.P.. Learn more on insiders at BCAX. What percentage of Bicara Therapeutics stock is owned by insiders? 15.50% of Bicara Therapeutics stock is owned by insiders. Learn more on BCAX's insider holdings. Which Bicara Therapeutics insiders have been buying company stock? The following insiders have purchased BCAX shares in the last 24 months: James E Flynn ($1,260,000.00), and Ra Capital Management, L.P. ($32,994,000.00). How much insider buying is happening at Bicara Therapeutics? Insiders have purchased a total of 1,903,000 BCAX shares in the last 24 months for a total of $34,254,000.00 bought. Bicara Therapeutics Key ExecutivesMs. Claire Mazumdar Clemon M.B.A. (Age 35)Ph.D., CEO & Director Compensation: $650kMr. Ryan Cohlhepp Pharm.D. (Age 48)President, COO & Director Compensation: $660kMr. Ivan Hyep M.B.A. (Age 40)Chief Financial Officer Compensation: $597.5kMs. Lara S. Meisner J.D. (Age 52)Chief Legal Officer & Corporate Secretary Ms. Rachel SalazarSVP of R&D Strategy and OperationsMs. Sathish Hasige Ph.D.Senior VP and Head of Technical Operations & Supply ChainDr. David Raben M.D. (Age 61)Chief Medical Officer Ms. Angela WindtVP & Head of Regulatory AffairsDr. Jeltje Schulten M.B.A.M.D., Senior Vice President of Clinical & Medical AffairsMr. Jean-Paul RodriqueSenior Vice President of Quality More Insider Trading Tools from MarketBeat Related Companies RXRX Insider Buying BHC Insider Buying AGIO Insider Buying ARWR Insider Buying KNSA Insider Buying TWST Insider Buying CNTA Insider Buying BEAM Insider Buying CGON Insider Buying DNLI Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles The Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months3 Small Caps Drawing Insider and Institutional Support This page (NASDAQ:BCAX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredThe AI Chip Trade is OUT. This is in…Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
